Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Moore M, Panjwani S, Mathew R, Crowley M, Liu Y-, Aronova A, et al. Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target. Endocr Pathol. 2017;28(4):339-344.

Postnikoff SD, Johnson JE, Tyler JK. The integrated stress response in budding yeast lifespan extension. Microb Cell. 2017;4(11):368-375.

Simon MS, Westblade LF, Dziedziech A, Visone JE, Furman RR, Jenkins SG, et al. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clin Infect Dis. 2017;65(7):1222-1225.

Khani F, Epstein JI. In response to 'a plea for greater standardization' in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology. 2017;70(6):1011-1013.

Ferraro RA, Ivanidze J, Margolskee E, Tsang H, Sconomiglio T, Jhanwar YS. Invasive granulomatous cryptococcal sinusitis in an adult with multiple myeloma. Clin Imaging. 2017;41:65-68.

Halteh P, Magro C, Scher RK, Lipner SR. Onychopapilloma Presenting as Leukonychia: Case Report and Review of the Literature. Skin Appendage Disord. 2017;2(3-4):89-91.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.

J Mulvey J, Matnani R, Cushing MM. Historical ABO blood group discrepancy: a blessing in disguise to unravel a medical identity theft. Transfusion. 2017;57(4):1096-1097.

Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma. Cell Metab. 2017;26(6):817-829.e6.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.